Speculation that Hospira (HSP -2.3%) shares have become so cheap in the face of scrutiny for...


Speculation that Hospira (HSP -2.3%) shares have become so cheap in the face of scrutiny for flaws in its manufacturing practices that the company may become a takeover target isn't helping the stock today. A potential FDA consent decree over alleged safety violations at one plant would slow production and perhaps even lead to a complete shutdown of the facility.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs